An overview of Pfizer within the biopharmaceutical sector, covering research, manufacturing, global distribution, and index ...
Despite Wall Street's continued conservatism regarding its business prospects, Pfizer beat analysts' expectations for the second quarter of 2024. In addition to the raised full-year 2024 guidance, the ...
Stocktwits on MSN
Pfizer leads new wave of 2026 US drug price hikes despite Trump’s drug cost crackdown: report
More medicines are slated for price hikes in 2026, with increases tracking around recent inflation levels. ・Only a few drugs ...
We are holding steady to our fair value estimate and wide moat rating for Pfizer PFE following first-quarter results that largely matched our expectations. The company is tracking well to meet its ...
The Daily Overview on MSN
How safe is Pfizer's dividend as 2026 begins?
Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback